{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:32:20Z","timestamp":1789705940615,"version":"4.0.1"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kidney transplant recipients (KTRs) are at an increased risk of osteoporosis, which negatively impacts their quality of life and transplant outcomes. However, the efficacy and safety of anti-osteoporosis treatments in this group remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic search of PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials up to August 1, 2024. Randomized controlled trials (RCTs) examining anti-osteoporotic medications in KTRs were included. Primary outcomes were changes in bone mineral density (BMD) at femoral neck and lumbar spine, and adverse events. We performed a frequentist network meta-analysis using random-effects models. Evidence certainty was assessed using the GRADE approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one RCTs involving 1,066 participants were included, published between 2000 and 2021. For femoral neck BMD, bisphosphonates significantly improved BMD compared to control (MD = 0.04, 95%CI=0.00-0.09, p&amp;lt;0.05) based on low certainty evidence, while calcitonin was significantly superior to calcium (MD=-0.14, 95%CI=-0.28 to -0.01). Most other comparisons showed no statistically significant differences based on very low to moderate certainty evidence. For lumbar spine BMD, bisphosphonates, calcitonin, and calcium demonstrated statistically significant inferiority compared to denosumab, with bisphosphonates showing MD=-4.98 (95%CI=-6.84 to -3.13), calcitonin showing MD=-4.35 (95%CI=-6.24 to -2.47), and calcium showing MD=-5.85 (95%CI=-7.72 to -3.98), while denosumab was superior to control (MD = 5.10, 95%CI=3.25-6.95), based on low to very low certainty evidence from one RCT. Calcitonin was also significantly superior to calcium (MD = 0.60, 95%CI=0.07-1.12). For safety outcomes, no statistically significant differences were observed between interventions based on low to moderate certainty evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Denosumab appears most effective for improving lumbar spine BMD in KTRs, while calcitonin shows promise for femoral neck BMD improvement. However, the low to moderate certainty of evidence necessitates individualized treatment approaches considering patient-specific factors including renal function and safety profiles. These findings suggest current guidelines emphasizing bisphosphonates as first-line therapy may require revision, though larger long-term studies with fracture endpoints are needed to confirm these results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/?utm_source=chatgpt.com<\/jats:uri>\n                      , identifier PROSPERO CRD42024587203.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1689233","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:22:05Z","timestamp":1762147325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative efficacy and safety of anti-osteoporotic therapies for kidney transplant recipients: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaopei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingmin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xili","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","first-page":"703","article-title":"Mineral and bone disease in kidney transplant recipients","volume-title":"Current osteoporosis reports","author":"Altman","year":"2018"},{"key":"B2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/medicina56060302","article-title":"Risk factors and management of osteoporosis post-transplant","volume":"56","author":"Kovvuru","year":"2020","journal-title":"Med (Kaunas Lithuania)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3390\/ijms25031859","article-title":"Post-transplant bone disease in kidney transplant recipients: diagnosis and management","volume":"25","author":"Teh","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003137","article-title":"Summary of the kidney disease: improving global outcomes (KDIGO) clinical practice guideline on the evaluation and management of candidates for kidney transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrology dialysis Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.07.006","article-title":"Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society","volume":"127","author":"Anastasilakis","year":"2019","journal-title":"Bone"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4158\/EP12016.RA","article-title":"Endocrine-metabolic pathophysiologic conditions and treatment approaches after kidney transplantation","volume":"18","author":"Gosmanova","year":"2012","journal-title":"Endocrine Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03410321","article-title":"Bone and mineral disease in kidney transplant recipients","volume":"17","author":"Khairallah","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3810\/pgm.2012.05.2551","article-title":"Bone disease in organ transplant patients: pathogenesis and management","volume":"124","author":"Chauhan","year":"2012","journal-title":"Postgraduate Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12792","article-title":"Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis","volume":"30","author":"Toth-Manikowski","year":"2016","journal-title":"Clin transplantation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3180a5e947","article-title":"Management of metabolic bone disease in kidney transplant recipients","volume":"335","author":"Zhang","year":"2008","journal-title":"Am J Med Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3465-7","article-title":"Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials","volume":"27","author":"Wang","year":"2016","journal-title":"Osteoporosis Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3906\/sag-1911-156","article-title":"Vitamin D receptor polymorphisms and bone health after kidney transplantation","volume":"51","author":"Korucu","year":"2021","journal-title":"Turkish J Med Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5414\/CN111234","article-title":"A retrospective study of mineral and bone disorder in kidney transplant recipients: Single-center experience","volume":"101","author":"Sun","year":"2024","journal-title":"Clin Nephrol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"Cd005015","DOI":"10.1002\/14651858.CD005015.pub4","article-title":"Interventions for preventing bone disease in kidney transplant recipients","volume":"10","author":"Palmer","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.12.006","article-title":"Interventions for preventing bone disease following kidney transplantation: is there evidence for specific therapy","volume":"75","author":"Sprague","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2013study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Internal Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Internal Emergency Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Res ed)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1037\/met0000405","article-title":"Robust Bayesian meta-analysis: Addressing publication bias with model-averaging","volume":"28","author":"Maier","year":"2023","journal-title":"Psychol Methods"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3758\/s13423-016-1015-8","article-title":"A simple introduction to Markov Chain Monte-Carlo sampling","volume":"25","author":"van Ravenzwaaij","year":"2018","journal-title":"Psychonomic Bull review"},{"key":"B28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res synthesis Methods"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00432.x","article-title":"Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation","volume":"65","author":"Torres","year":"2004","journal-title":"Kidney Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12882-023-03376-y","article-title":"The effect of zoledronic acid on hip geometry in renal transplant recipients: a double-blind placebo-controlled randomized study","volume":"24","author":"Dabbaghmanesh","year":"2023","journal-title":"BMC Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000093255.56474.B4","article-title":"Preventing bone loss in renal transplant recipients with vitamin D","volume":"14","author":"El-Agroudy","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.01.065","article-title":"Effect of bisphosphonates on bone mineral density after renal transplantation as assessed by bone mineral densitometry","volume":"39","author":"Nayak","year":"2007","journal-title":"Transplant Proc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018060656","article-title":"A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation","volume":"30","author":"Marques","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1197-2","article-title":"Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant","volume":"22","author":"Torregrosa","year":"2011","journal-title":"Osteoporosis Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000092523.30277.13","article-title":"Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate","volume":"76","author":"Jeffery","year":"2003","journal-title":"Transplantation"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04233.x","article-title":"A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation","volume":"12","author":"Smerud","year":"2012","journal-title":"Am J Transplant"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13692","article-title":"Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: A randomized controlled trial","volume":"16","author":"Bonani","year":"2016","journal-title":"Am J Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4469","article-title":"Cholecalciferol supplementation attenuates bone loss in incident kidney transplant recipients: A prespecified secondary endpoint analysis of a randomized controlled trial","volume":"37","author":"Tsujita","year":"2022","journal-title":"J Bone mineral Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011060623","article-title":"Effect of risedronate on bone in renal transplant recipients","volume":"23","author":"Coco","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1271530","article-title":"Effect of ibandronate on bone loss and renal function after kidney transplantation","volume":"12","author":"Grotz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.243","article-title":"Comments on \u2018KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease\u2019","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Adeera","year":"2024","journal-title":"Kidney Int"},{"key":"B43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","author":"Kasiske","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.989648","article-title":"Expert consensus on the bone repair strategy for osteoporotic fractures in China","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann rheumatic Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1456796","article-title":"Osteoporosis treatment: current drugs and future developments","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.228252","article-title":"Efficacy and safety of different bisphosphonates for bone loss prevention in kidney transplant recipients: A network meta-analysis of randomized controlled trials","volume":"131","author":"Yang","year":"2018","journal-title":"Chin Med J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"B50","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12966-020-01040-4","article-title":"Evidence on physical activity and osteoporosis prevention for people aged 65+ years: a systematic review to inform the WHO guidelines on physical activity and sedentary behaviour","volume":"17","author":"Pinheiro","year":"2020","journal-title":"Int J Behav Nutr Phys activity"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.256180","article-title":"Bone mineral density: clinical relevance and quantitative assessment","volume":"62","author":"Haseltine","year":"2021","journal-title":"J Nucl Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2019.00006","article-title":"The bone-vasculature axis: calcium supplementation and the role of vitamin K","volume":"6","author":"Wasilewski","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.576110","article-title":"Disorders of calcium and phosphorus metabolism and the proteomics\/metabolomics-based research","volume":"8","author":"Sun","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.992666","article-title":"FGF-23, Klotho and Vitamin D as regulators of calcium and phosphorus: Genetics, epigenetics and beyond","volume":"13","author":"Portales-Castillo","year":"2022","journal-title":"Front endocrinology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1133828","article-title":"Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of Malignant tumors, including pharmacological mechanism and clinical trials","volume":"13","author":"Lu","year":"2023","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1017\/cem.2019.490","article-title":"Efficacy of calcitonin for treating acute pain associated with osteoporotic vertebral compression fracture: an updated systematic review","volume":"22","author":"Boucher","year":"2020","journal-title":"Cjem"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4283","article-title":"Bisphosphonates in kidney disease-safety first","volume":"36","author":"Khairallah","year":"2021","journal-title":"J Bone mineral Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12882-018-1076-1","article-title":"Outcomes of bisphosphonate and its supplements for bone loss in kidney transplant recipients: a systematic review and network meta-analysis","volume":"19","author":"Yang","year":"2018","journal-title":"BMC Nephrol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02327.x","article-title":"Effect of teriparatide on early bone loss after kidney transplantation","volume":"8","author":"Cejka","year":"2008","journal-title":"Am J Transplant"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03872.x","article-title":"Reduced fracture risk with early corticosteroid withdrawal after kidney transplant","volume":"12","author":"Nikkel","year":"2012","journal-title":"Am J Transplant"},{"key":"B61","doi-asserted-by":"publisher","first-page":"100474","DOI":"10.1016\/j.xkme.2022.100474","article-title":"Kidney transplantation, immunosuppression and the risk of fracture: clinical and economic implications","volume":"4","author":"Kuppachi","year":"2022","journal-title":"Kidney Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11657-021-00971-0","article-title":"Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety","volume":"16","author":"Gopaul","year":"2021","journal-title":"Arch osteoporosis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1689233\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:22:07Z","timestamp":1762147327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1689233\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":62,"alternative-id":["10.3389\/fendo.2025.1689233"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1689233","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1689233"}}